MedPath

Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)

Phase 4
Completed
Conditions
Neoplasms
Nausea
Vomiting
Interventions
Drug: Palonosetron
First Posted Date
2008-05-26
Last Posted Date
2017-05-16
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
59
Registration Number
NCT00684463

A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)

Phase 2
Completed
Conditions
Psoriasis
Interventions
Other: Placebo
Drug: Navarixin 10 mg
First Posted Date
2008-05-26
Last Posted Date
2019-02-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
31
Registration Number
NCT00684593

Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)

Phase 4
Completed
Conditions
Herpes Zoster
Interventions
Biological: ZOSTAVAX®
First Posted Date
2008-05-20
Last Posted Date
2021-06-29
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
96
Registration Number
NCT00681031

A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease

Phase 2
Completed
Conditions
Dry Eye Disease
First Posted Date
2008-05-19
Last Posted Date
2015-08-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
150
Registration Number
NCT00679718

A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution

Phase 2
Completed
Conditions
Dry Eye Disease
First Posted Date
2008-05-19
Last Posted Date
2015-08-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
62
Registration Number
NCT00680108

A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)

Phase 1
Terminated
Conditions
Peripheral Vascular Diseases
Interventions
Drug: MK-0736
First Posted Date
2008-05-16
Last Posted Date
2018-08-17
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
14
Registration Number
NCT00679055

Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)

Phase 3
Completed
Conditions
Anesthesia
Interventions
Drug: Sugammadex
Drug: Neostigmine
Drug: Rocuronium
First Posted Date
2008-05-12
Last Posted Date
2015-03-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
100
Registration Number
NCT00675792

Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED)

Phase 2
Completed
Conditions
Seasonal Allergic Rhinitis
Interventions
Drug: SCH 900538
Drug: Pseudoephedrine
Drug: Placebo Capsules
First Posted Date
2008-05-07
Last Posted Date
2015-11-01
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
265
Registration Number
NCT00673062

Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED)

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: SCH 497079
Drug: Placebo
Drug: Metformin
First Posted Date
2008-05-07
Last Posted Date
2018-09-10
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
17
Registration Number
NCT00673465

Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)

Phase 1
Completed
Conditions
Locally Advanced Tumors
Metastatic Solid Tumors
Neoplasms
Cancer
Interventions
Drug: MK-2206
First Posted Date
2008-05-01
Last Posted Date
2019-04-01
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
104
Registration Number
NCT00670488
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy